Skip to main content
PMC home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 2003 Jun;79(3):191–196. doi: 10.1136/sti.79.3.191

Prospective study on cervical neoplasia: presence of HPV DNA in cytological smears precedes the development of cervical neoplastic lesions

R Tachezy 1, M Salakova 1, E Hamsikova 1, J Kanka 1, A Havrankova 1, V Vonka 1
PMCID: PMC1744668  PMID: 12794200

Abstract

Objectives: The principal aim of the study was to verify whether HPV infection in healthy women, as determined by HPV DNA detection, was associated with an increased risk of development of cervical lesions.

Methods: Cervical smears collected at enrolment into the prospective study conducted in Prague during 1975–83 were tested for the presence of HPV DNA by means of a polymerase chain reaction (PCR) using the general GP5/6 primers and a mixture of primers specific for the E6 gene. 120 smears from patients in whom cervical neoplasia had been detected in the course of the prospective study and 208 smears from control women who had remained healthy throughout the observation period were analysed. Patients and controls were matched by age, number of sexual partners, age at first intercourse, and smoking habit. Patients were divided into three groups, A, B, and C, according to their cytological, colposcopic, and histological findings at enrolment. Group A consisted of 67 women found ill at enrolment, group B of 26 women with slightly suspicious findings, while group C comprised 27 women with normal findings at enrolment. In addition, sera taken at enrolment from these patients and controls were tested for the presence of antibodies reactive with virus-like particles (VLPs) of HPV 16, 18, and 33.

Results: For the whole cohort, there was a statistically highly significant difference in the presence of HPV DNA between patients and controls. Furthermore, the difference in the presence of HPV DNA between patients and controls was highly significant not only in those who had been found ill at enrolment (group A) but, most importantly, also in women who had developed the disease in the course of the follow up (groups B and C). Women positive for HPV DNA possessed HPV antibodies to VLP16, 18 and 33 significantly more often than those who were free of HPV DNA.

Conclusion: This indicated that healthy women who were positive for HPV DNA at enrolment were at an increased risk of developing cervical neoplasia (OR = 18.5; CI 5.9 to 57.6).

Full Text

The Full Text of this article is available as a PDF (119.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler M. W. Sexual health--health of the nation. Sex Transm Infect. 2003 Apr;79(2):85–87. doi: 10.1136/sti.79.2.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bauer H. M., Ting Y., Greer C. E., Chambers J. C., Tashiro C. J., Chimera J., Reingold A., Manos M. M. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991 Jan 23;265(4):472–477. [PubMed] [Google Scholar]
  3. Carter J. J., Koutsky L. A., Hughes J. P., Lee S. K., Kuypers J., Kiviat N., Galloway D. A. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000 May 31;181(6):1911–1919. doi: 10.1086/315498. [DOI] [PubMed] [Google Scholar]
  4. Carter J. J., Koutsky L. A., Wipf G. C., Christensen N. D., Lee S. K., Kuypers J., Kiviat N., Galloway D. A. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996 Nov;174(5):927–936. doi: 10.1093/infdis/174.5.927. [DOI] [PubMed] [Google Scholar]
  5. De Sanjosé S., Hamsíková E., Muñoz N., Bosch F. X., Hofmannová V., Gili M., Izarzugaza I., Viladiu P., Tormo M. J., Moreo P. Serological response to HPV16 in CIN-III and cervical cancer patients. Case-control studies in Spain and Colombia. Int J Cancer. 1996 Mar 28;66(1):70–74. doi: 10.1002/(SICI)1097-0215(19960328)66:1<70::AID-IJC13>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  6. Dillner J., Lehtinen M., Björge T., Luostarinen T., Youngman L., Jellum E., Koskela P., Gislefoss R. E., Hallmans G., Paavonen J. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst. 1997 Sep 3;89(17):1293–1299. doi: 10.1093/jnci/89.17.1293. [DOI] [PubMed] [Google Scholar]
  7. Dürst M., Gissmann L., Ikenberg H., zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3812–3815. doi: 10.1073/pnas.80.12.3812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dürst M., Kleinheinz A., Hotz M., Gissmann L. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J Gen Virol. 1985 Jul;66(Pt 7):1515–1522. doi: 10.1099/0022-1317-66-7-1515. [DOI] [PubMed] [Google Scholar]
  9. Friedl F., Kimura I., Osato T., Ito Y. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med. 1970 Nov;135(2):543–545. doi: 10.3181/00379727-135-35091a. [DOI] [PubMed] [Google Scholar]
  10. Hamsiková E., Novák J., Hofmannová V., Munoz N., Bosch F. X., de Sanjosé S., Shah K., Roth Z., Vonka V. Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. J Infect Dis. 1994 Dec;170(6):1424–1431. doi: 10.1093/infdis/170.6.1424. [DOI] [PubMed] [Google Scholar]
  11. Ho G. Y., Burk R. D., Klein S., Kadish A. S., Chang C. J., Palan P., Basu J., Tachezy R., Lewis R., Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995 Sep 20;87(18):1365–1371. doi: 10.1093/jnci/87.18.1365. [DOI] [PubMed] [Google Scholar]
  12. Kirnbauer R., Hubbert N. L., Wheeler C. M., Becker T. M., Lowy D. R., Schiller J. T. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst. 1994 Apr 6;86(7):494–499. doi: 10.1093/jnci/86.7.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kjaer S. K., van den Brule A. J., Bock J. E., Poll P. A., Engholm G., Sherman M. E., Walboomers J. M., Meijer C. J. Human papillomavirus--the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer. 1996 Mar 1;65(5):601–606. doi: 10.1002/(SICI)1097-0215(19960301)65:5<601::AID-IJC8>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  14. Krcmár M., Suchánková A., Kanka J., Vonka V. Prospective study on the relationship between cervical neoplasia and herpes simplex type 2 virus. III. Presence of herpes simplex type-2 antibody in sera of subjects who developed cervical neoplasia later in the study. Int J Cancer. 1986 Aug 15;38(2):161–165. doi: 10.1002/ijc.2910380203. [DOI] [PubMed] [Google Scholar]
  15. Kutinová L., Vonka V., Rezácová D. Plaque formation by NWS influenza virus in a human diploid cell strain. Acta Virol. 1967 Jul;11(4):372–378. [PubMed] [Google Scholar]
  16. Lehtinen M., Dillner J., Knekt P., Luostarinen T., Aromaa A., Kirnbauer R., Koskela P., Paavonen J., Peto R., Schiller J. T. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ. 1996 Mar 2;312(7030):537–539. doi: 10.1136/bmj.312.7030.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Liaw K. L., Glass A. G., Manos M. M., Greer C. E., Scott D. R., Sherman M., Burk R. D., Kurman R. J., Wacholder S., Rush B. B. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst. 1999 Jun 2;91(11):954–960. doi: 10.1093/jnci/91.11.954. [DOI] [PubMed] [Google Scholar]
  18. Lungu O., Sun X. W., Wright T. C., Jr, Ferenczy A., Richart R. M., Silverstein S. A polymerase chain reaction-enzyme-linked immunosorbent assay method for detecting human papillomavirus in cervical carcinomas and high-grade cervical cancer precursors. Obstet Gynecol. 1995 Mar;85(3):337–342. doi: 10.1016/0029-7844(94)00399-x. [DOI] [PubMed] [Google Scholar]
  19. Melkert P. W., Hopman E., van den Brule A. J., Risse E. K., van Diest P. J., Bleker O. P., Helmerhorst T., Schipper M. E., Meijer C. J., Walboomers J. M. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993 Apr 1;53(6):919–923. doi: 10.1002/ijc.2910530609. [DOI] [PubMed] [Google Scholar]
  20. Nonnenmacher B., Hubbert N. L., Kirnbauer R., Shah K. V., Muñoz N., Bosch F. X., de Sanjosé S., Viscidi R., Lowy D. R., Schiller J. T. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis. 1995 Jul;172(1):19–24. doi: 10.1093/infdis/172.1.19. [DOI] [PubMed] [Google Scholar]
  21. Remmink A. J., Walboomers J. M., Helmerhorst T. J., Voorhorst F. J., Rozendaal L., Risse E. K., Meijer C. J., Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995 May 4;61(3):306–311. doi: 10.1002/ijc.2910610305. [DOI] [PubMed] [Google Scholar]
  22. Saiki R. K., Scharf S., Faloona F., Mullis K. B., Horn G. T., Erlich H. A., Arnheim N. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985 Dec 20;230(4732):1350–1354. doi: 10.1126/science.2999980. [DOI] [PubMed] [Google Scholar]
  23. Schwarz E., Freese U. K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985 Mar 7;314(6006):111–114. doi: 10.1038/314111a0. [DOI] [PubMed] [Google Scholar]
  24. Snijders P. J., Meijer C. J., Walboomers J. M. Degenerate primers based on highly conserved regions of amino acid sequence in papillomaviruses can be used in a generalized polymerase chain reaction to detect productive human papillomavirus infection. J Gen Virol. 1991 Nov;72(Pt 11):2781–2786. doi: 10.1099/0022-1317-72-11-2781. [DOI] [PubMed] [Google Scholar]
  25. Snijders P. J., van den Brule A. J., Schrijnemakers H. F., Snow G., Meijer C. J., Walboomers J. M. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol. 1990 Jan;71(Pt 1):173–181. doi: 10.1099/0022-1317-71-1-173. [DOI] [PubMed] [Google Scholar]
  26. Stöppler H., Stöppler M. C., Schlegel R. Transforming proteins of the papillomaviruses. Intervirology. 1994;37(3-4):168–179. doi: 10.1159/000150375. [DOI] [PubMed] [Google Scholar]
  27. Tachezy R., Hamsíková E., Hájek T., Mikysková I., Smahel M., Van Ranst M., Kanka J., Havránková A., Rob L., Guttner V. Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol. 1999 Aug;58(4):378–386. doi: 10.1002/(sici)1096-9071(199908)58:4<378::aid-jmv10>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  28. Tachezy R., Van Ranst M. A., Cruz Y., Burk R. D. Analysis of short novel human papillomavirus sequences. Biochem Biophys Res Commun. 1994 Oct 28;204(2):820–827. doi: 10.1006/bbrc.1994.2533. [DOI] [PubMed] [Google Scholar]
  29. Van Den Brule A. J., Walboomers J. M., Du Maine M., Kenemans P., Meijer C. J. Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer. 1991 May 30;48(3):404–408. doi: 10.1002/ijc.2910480317. [DOI] [PubMed] [Google Scholar]
  30. Viladiu P., Bosch F. X., Castellsagué X., Muñoz N., Escribà J. M., Hamsíkova E., Hofmannova V., Guerrero E., Izquierdo A., Navarro C. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. J Clin Oncol. 1997 Feb;15(2):610–619. doi: 10.1200/JCO.1997.15.2.610. [DOI] [PubMed] [Google Scholar]
  31. Vonka V., Hamsíková E., Kanka J., Ludvíková V., Sapp M., Smahel M. Prospective study on cervical neoplasia IV. Presence of HPV antibodies. Int J Cancer. 1999 Jan 29;80(3):365–368. doi: 10.1002/(sici)1097-0215(19990129)80:3<365::aid-ijc5>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  32. Vonka V., Kanka J., Hirsch I., Závadová H., Krcmár M., Suchánková A., Rezácová D., Broucek J., Press M., Domorázková E. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int J Cancer. 1984 Jan 15;33(1):61–66. doi: 10.1002/ijc.2910330111. [DOI] [PubMed] [Google Scholar]
  33. Vonka V., Kanka J., Jelínek J., Subrt I., Suchánek A., Havránková A., Váchal M., Hirsch I., Domorázková E., Závadová H. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. I. Epidemiological characteristics. Int J Cancer. 1984 Jan 15;33(1):49–60. doi: 10.1002/ijc.2910330110. [DOI] [PubMed] [Google Scholar]
  34. Wagatsuma M., Hashimoto K., Matsukura T. Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flanking sequences. J Virol. 1990 Feb;64(2):813–821. doi: 10.1128/jvi.64.2.813-821.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Walboomers J. M., Jacobs M. V., Manos M. M., Bosch F. X., Kummer J. A., Shah K. V., Snijders P. J., Peto J., Meijer C. J., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12–19. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  36. Yee L. J., Rhodes S. D. Understanding correlates of hepatitis B virus vaccination in men who have sex with men: what have we learned? Sex Transm Infect. 2002 Oct;78(5):374–377. doi: 10.1136/sti.78.5.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. de Gruijl T. D., Bontkes H. J., Walboomers J. M., Schiller J. T., Stukart M. J., Groot B. S., Chabaud M. M., Remmink A. J., Verheijen R. H., Helmerhorst T. J. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst. 1997 May 7;89(9):630–638. doi: 10.1093/jnci/89.9.630. [DOI] [PubMed] [Google Scholar]
  38. de Roda Husman A. M., Walboomers J. M., Meijer C. J., Risse E. K., Schipper M. E., Helmerhorst T. M., Bleker O. P., Delius H., van den Brule A. J., Snijders P. J. Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. Int J Cancer. 1994 Mar 15;56(6):802–806. doi: 10.1002/ijc.2910560607. [DOI] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES